In 2024, Eli Lilly and Co completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Eli Lilly and Co has also provided a category-level breakdown for 13 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 192,000a | 182,000a | 171,000a | |
Total Scope 2 | ||||
Market-Based | 258,000a | 345,000a | 374,000a | |
Location-Based | 396,000b | N/A | N/A | |
Total Scope 3 | 6,173,761b | 5,139,500a | 3,179,000d | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 4.2626a | 5.3335a | 5.9913a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Eli Lilly and Co amounted to 588,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).ab
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Eli Lilly and Co increased by 11.57%, suggesting that the company faced challenges in reducing its emissions from its core operations.ab
In 2024, the total Scope 1 emissions of Eli Lilly and Co were 192,000 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Eli Lilly and Co's Scope 1 emissions have remained relatively, stable, indicating that Eli Lilly and Co's emissions have plateaued with no significant change in its operational footprint.ab
Compared to the previous year (2023), Eli Lilly and Co's Scope 1 emissions increased by 5.49%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2024, Eli Lilly and Co reported Scope 2 greenhouse gas (GHG) emissions of 258,000 tCO₂e using the market-based method and 396,000 tCO₂e using the location-based method.ab
Since 2019, Eli Lilly and Co's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have decreased by 33.56%, reflecting a declining long-term trend in Scope 2 emissions over time.b
In 2024, Eli Lilly and Co reported its Scope 2 emissions using the market-based method and using the location-based method.ab
In 2024, Eli Lilly and Co reported 6,173,761 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.b
The 2024 disclosure of Eli Lilly and Co includes a breakdown across 13 of the 15 Scope 3 categories defined by the GHG Protocol, up from 10 in 2023, reflecting improved emissions accounting practices and greater transparency across the company's value chainb
In 2024, Eli Lilly and Co reported total Scope 3 emissions of 6,173,761 metric tons of CO₂ equivalent (tCO₂e).b
Approximately 98.44% of these emissions originated from upstream activities such as purchased goods and capital goods, while 1.56% came from downstream activities like product use, distribution, and end-of-life treatment.b
Since 2019, Eli Lilly and Co's Scope 3 emissions have increased by 2,527.13%, reflecting a rising long-term trend in Scope 3 emissions over time.be
Compared to the previous year (2023), Eli Lilly and Co's Scope 3 emissions increased by 20.12%, suggesting that the company faced challenges in reducing emissions across its value chain.ab
In 2024, Eli Lilly and Co reported emissions for 13 out of the 15 Scope 3 categories defined by the GHG Protocol.b
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Eli Lilly and Co's Scope 3 emissions were:b
In 2024, Eli Lilly and Co reported Scope 1 greenhouse gas (GHG) emissions of 192,000 tCO₂e and total revenues of USD 45,043 millions. This translates into an emissions intensity of 4.26 tCO₂e per millions USD.a
In 2024, Eli Lilly and Co reported a Scope 1 emissions intensity of 4.26 tCO₂e per millions USD. Compared to the peer group median of 5.34, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Eli Lilly and Co ranked 10 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Eli Lilly and Co is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Eli Lilly and Co reported a total carbon footprint of 6,761,761 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 19.33% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.ab
The largest contributor to Eli Lilly and Co's total carbon footprint was Scope 3 emissions, accounting for 91.3% of the company's total carbon footprint, followed by Scope 2 emissions at 5.86%.b